Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.32 USD
Change Today +0.03 / 1.31%
Volume 291.7K
GEVO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

gevo inc (GEVO) Snapshot

Open
$2.25
Previous Close
$2.29
Day High
$2.35
Day Low
$2.21
52 Week High
11/25/14 - $8.03
52 Week Low
04/21/15 - $1.32
Market Cap
38.3M
Average Volume 10 Days
758.9K
EPS TTM
$-4.31
Shares Outstanding
16.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GEVO INC (GEVO)

gevo inc (GEVO) Related Businessweek News

No Related Businessweek News Found

gevo inc (GEVO) Details

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The company operates in two segments, Gevo, Inc.; and Gevo Development/Agri-Energy. The company engages in the research and development, and production of isobutanol; development of its proprietary biocatalysts; production and sale of biojet fuel; and retrofit process of chemicals and biofuels. It is also involved in the production of ethanol, isobutanol, and related products. Gevo, Inc. produces and separates its renewable isobutanol through the Gevo Integrated Fermentation Technology platform. The company was formerly known as Methanotech, Inc. and changed its name to Gevo, Inc. in March 2006. Gevo, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

97 Employees
Last Reported Date: 03/30/15
Founded in 2005

gevo inc (GEVO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $750.0K
President, Chief Operating Officer and Chief ...
Total Annual Compensation: $469.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $478.3K
Chief Legal Officer, General Counsel and Secr...
Total Annual Compensation: $455.0K
Chief Commercial Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

gevo inc (GEVO) Key Developments

Butamax Advanced Biofuels, LLC and Gevo, Inc. Enter into Global Patent Cross-License and Settlement Agreements to Accelerate Development of Markets for Bio-Based Isobutanol and End All Litigation

Gevo, Inc. and Butamax Advanced Biofuels, LLC, a joint venture between BP and DuPont, announced that they have entered into worldwide patent cross-license and settlement agreements, ending a patent dispute related to technologies for the production of bio-based isobutanol. This settlement ends all of the lawsuits and creates a new relationship between the companies, aimed at leveraging each other's strengths and accelerating development of competitive supply for bio-based isobutanol. The cross-license agreement grants both parties patent licenses to all fields for isobutanol and is structured to develop robust and sustainable isobutanol markets. The license will be royalty bearing for Butamax in certain fields and royalty bearing for Gevo in other fields. There are also a number of fields that are royalty-free for both companies. Both parties can sell up to 30 million gallons per year royalty-free into any field. Butamax will take the lead role in developing the market for isobutanol as an on-road gasoline blendstock. This will include progressing ongoing programs to gain required EPA approvals for mainstream use of 16% isobutanol as a gasoline blend component. Butamax has also conducted joint research with Underwriters Laboratories (UL), which has demonstrated that these blends can be used safely in fuel storage and dispensing equipment meeting current UL standards. It is expected that UL's guidance will clear the way for state government agencies to consider and approve the dispensing of biobutanol-gasoline fuel blends in the U.S. In parallel, Gevo will lead development of the jet fuel market. Gevo has been producing and selling alcohol-to-jet fuel (ATJ) derived from isobutanol since 2011. To date, Gevo's ATJ has been produced at its demo biorefinery in Silsbee, TX, using isobutanol produced at its Luverne, MN, fermentation facility. The company has successfully flown tests flights with the U.S. Air Force, U.S. Army, and U.S. Navy and now expects to secure the MIL-SPEC certification (JP-8 and JP-5) enabling bids on future RFPs for renewable jet fuel by the Defense Logistics Agency. Gevo also intends to begin test flights with the commercial aviation industry, including Alaska Airlines, following receipt of ASTM International certification, expected before the end of 2015. While Butamax and Gevo have cross-licensed all of their patents for making and using isobutanol, both parties will have their own biocatalyst and process technologies. Both Butamax and Gevo are free to license their respective technology packages to third parties. A third party licensee would be granted a sub-license, and would be subject to terms and conditions that are consistent with the cross-license between Butamax and Gevo.

Gevo, Inc. Reports Unaudited Consolidated and Company Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Gevo, Inc. reported unaudited consolidated and company earnings results for the second quarter and six months ended June 30, 2015. For the quarter, on consolidated basis, the company reported total revenues of $8.924 million compared to $7.721 million a year ago. Loss from operations was of $6.531 million compared to $9.032 million a year ago. Net loss was $17.802 million compared to $17.156 million a year ago. Basic and diluted net loss per share attributable to company common stockholders was $1.36 against $3.79 a year ago. Non-GAAP loss from operations was $4,616,000 against $7,617,000 a year ago. The increase in revenue during 2015 is primarily a result of the production and sale of approximately $8.0 million of ethanol, isobutanol and distiller’s grains at the Luverne plant. For six months, on consolidated basis, the company reported total revenues of $14.823 million compared to $8.624 million a year ago. Loss from operations was of $16.067 million compared to $21.954 million a year ago. Net loss was $25.145 million compared to $29.128 million a year ago. Net cash used in operating activities was $14.885 million compared to $25.220 million a year ago. Acquisitions of property, plant and equipment was $0.175 million compared to $3.837 million a year ago. Basic and diluted net loss per share attributable to company common stockholders was $2.35 against $6.44 a year ago. Non-GAAP loss from operations was $12,088,000 against $19,713,000 a year ago. For the quarter, the company’s loss from operations was of $4.440 million compared to $5.979 million a year ago. Non-GAAP loss from operations was $3,942,000 against $19,713,000 a year ago. For the six months, the company’s loss from operations was of $9.664 million compared to $13.833 million a year ago. Non-GAAP loss from operations was $8,551,000 against $12,746,000 a year ago.

Gevo, Inc. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 11:20 AM

Gevo, Inc. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 11:20 AM. Venue: Grand Hyatt, 109 E. 42nd Street, New York, New York, United States. Speakers: Patrick R. Gruber, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVO:US $2.32 USD +0.03

GEVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aemetis Inc $3.02 USD -0.014
Bluefire Renewables Inc $0.0055 USD -0.0007
Global Bioenergies SA €38.98 EUR -0.30
METabolic EXplorer SA €3.26 EUR -0.05
Solazyme Inc $2.61 USD +0.15
View Industry Companies
 

Industry Analysis

GEVO

Industry Average

Valuation GEVO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GEVO INC, please visit www.gevo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.